Lufax Holding Ltd vs Tempus AI — how do they compare? Lufax Holding Ltd trades at $0.99 (market cap $982.89M), while Tempus AI trades at $71.3 (market cap $12.58B). The key difference: Tempus AI is far larger — about 12.8× Lufax Holding Ltd's market cap, and Tempus AI is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Tempus AI for 23 Days on average.
| LU | TEM | |
|---|---|---|
Market Cap | $982.89M | $12.58B |
Volume | 3,323,384 | 7,444,569 |
Sector | Financials | Broad Market / Factor |
52-Week High | $3.93 | $99.28 |
52-Week Low | $0.95 | $41.55 |
Typical Hold Time | 13 Days | 23 Days |
Enterprise Value | $58.81B | $13.21B |
Signals from Pluang's Aura AI — not financial advice
Lufax (LU) trades at $0.986, up 0.47% on the day, but shows significant fundamental challenges with consecutive quarterly losses and declining revenue. The company recently completed a 10:1 reverse stock split and faces bearish technical signals despite some oversold RSI readings. Analyst sentiment remains predominantly bullish with 69% buy ratings, pointing to potential value in the depressed valuation multiples.
The investment case hinges on Lufax's deep value proposition trading at 0.07x book value, but requires successful navigation of regulatory headwinds and return to profitability. Key risks include persistent net losses, Chinese regulatory uncertainty, and declining top-line performance that could pressure the stock further despite strong institutional backing from parent company Ping An.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →